Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the pharmacokinetics, safety, and tolerability of a fixed dose combination of two drugs, cefepime and enmetazobactam, given intravenously to children from birth up to less than 18 years old who are hospitalized with complicated urinary tract infections cUTI. This phase 2 study supports regulatory requirements in the US and Europe to extend cefepime-enmetazobactam use to pediatric patients with cUTI. Participants receive cefepime and enmetazobactam together as a fixed dose combination administered intravenously over two hours every 8 hours. Treatment lasts between 3 and 7 days, depending on how quickly infection symptoms resolve. Participants remain hospitalized during treatment and have follow-up visits 7 and 14 days after treatment ends, with a final study visit conducted by phone or in person 28 days after treatment completion. Throughout the study, participants undergo blood tests to measure drug levels and monitoring for safety and tolerability from before the first dose until 28 days after treatment. Researchers assess infection symptoms and collect urine cultures. Follow-up visits ensure recovery and evaluate treatment effects. The total participation time spans about a month from treatment start to final follow-up.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of AZD4144 in adults aged 18 to 80 years with sepsis-associated acute kidney injury. This Phase IIa, randomized, double-blind, placebo-controlled study includes participants who have sepsis caused by suspected or confirmed bacterial infection requiring vasopressor or inotrope treatment and developed acute kidney injury within 72 hours of sepsis onset. Participants will be randomly assigned to receive either intravenous AZD4144 or a matching placebo once daily for a fixed treatment period. During this time, daily safety monitoring and collection of blood and urine samples will occur. After treatment, participants will continue to be monitored daily while hospitalized and will have up to two follow-up visits after discharge to assess safety and kidney function. Throughout the study, researchers will measure kidney function markers such as 24-hour creatinine clearance and other related outcomes. Additional assessments include monitoring days alive without kidney replacement therapy, mechanical ventilation, or hospitalization over approximately 30 days. Safety and tolerability will be closely observed during and after treatment, with the total participation spanning screening, treatment, hospitalization monitoring, and post-discharge follow-up visits.
Actively Recruiting
Researchers are studying which of three eye drop medicationsbromfenac 0.09%, nepafenac 0.3%, and diclofenac 0.1%is more effective in preventing and treating cystoid macular oedema following cataract surgery. The study aims to find out which drug better prevents this condition and to compare the medical problems participants might have when using different drugs. Participants will be randomly assigned to use one of these drugs before and after their cataract surgery. Participants will use eye drops in their operated eye for up to 26 days, starting four days before surgery and continuing for 21 days after. The bromfenac group applies drops twice daily, the nepafenac group once daily, and the diclofenac group four times daily. This dosing schedule is followed throughout the treatment period to assess and compare the drugs effects. During the study, participants will visit the clinic for exams on the first day, one week, three weeks, and six weeks after surgery. Assessments include retina examination using optical coherence tomography OCT, vision tests, and questionnaires about their quality of life. Researchers will track the presence of macular oedema over six weeks and monitor changes in vision-related quality of life. The total participation lasts about six weeks after surgery with regular follow-up visits.
Actively Recruiting
This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.
Actively Recruiting
Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.